Video

Dermatologic Reactions to the COVID-19 Vaccine

Author(s):

Esther Freeman, MD, PhD, discusses the most frequent cutaneous presentations associated with vaccination.

Esther Freeman, MD, PhD, of Massachusetts General Hospital, is the principal investigator of the COVID-19 Dermatology Registry, a database developed in collaboration with the American Academy of Dermatology (AAD) and the International League of Dermatologic Societies (ILDS).

For months, the registry has collected cases of dermatologic manifestations related to COVID-19 so that dermatologists and care providers can be informed on the possible skin manifestations related to infection.

“At this point we’ve collected over 2000 cases of dermatologic manifestations of COVID-19 from 52 different countries and from all continents except Antarctica ,” noted Freeman in an interview with HCPLive®.

Since the start of the international vaccination campaign, the registry has also begun to include information on symptoms and presentations associated with the Pfizer and Moderna mRNA vaccines.

Freeman discussed her team's most recently published data, which was based on the first 414 vaccine skin reactions.

“The most commonly reported reaction was actually after Moderna,” said Freeman. “And this is something called a delayed large local reaction.”

She explained it presents as a large red plaque on the arm 7 or 8 days following injection. Patients nonetheless do very well. Thus, Freeman noted, it becomes the responsibility of the provider to assure and educate their patients about such possible reactions.

Other possible common reactions include urticaria, morbilliform, and COVID toes, said Freeman.

Related Videos
Comparing Treatment Options for Psoriatic Arthritis with Philip Mease, MD
HCPLive Five at Maui Derm NP+PA Fall 2024 | Image Credit: HCPLive
Ashfaq Marghoob, MD: Artificial Intelligence, Smartphone Use for Pigmented Lesion Classification
Steve Nissen, MD | Credit: Cleveland Clinic
Major Diagnostic Challenges for Pigmented Lesions, with Ashfaq Marghoob, MD
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Considering Viral Infections in Patients With Rheumatic Disease With Leonard Calabrese, DO
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
Benjamin Scirica, MD | Credit: Brigham and Women's Hospital
© 2024 MJH Life Sciences

All rights reserved.